Ionis must prove it can sell after a major setback
- Ionis is no longer mainly a research partner story. It now has direct U.S. launches to execute.
- Tryngolza won FDA approval for severe hypertriglyceridemia in June 2026, turning a key regulatory risk into a launch risk.
- The WAINUA CARDIO-TTRansform trial missed its primary endpoint in July 2026, wiping out a massive potential royalty stream.
- Management previously raised 2026 revenue guidance to between $875 million and $900 million.
- Finn scores remain cautious because Ionis is spending heavily on launches while absorbing clinical setbacks.
Setbacks move the burden to sales
The big change is the dual nature of recent events. Tryngolza was approved by the FDA for severe hypertriglyceridemia in June 2026, and management noted strong early launch metrics including day one prescriptions. But a month later, the partnered WAINUA cardiovascular trial failed to meet its primary endpoint in the overall population. This means the key question is no longer about expanding royalties, but whether Ionis can succeed in direct sales.
The bull case hinges on Tryngolza. If the drug ramps fast in the second half of 2026 and Dawnzera keeps gaining in hereditary angioedema, Ionis can stay on track toward cash flow breakeven by 2028. The approval in sHTG opens a large market and solidifies the transition to a commercial powerhouse.
The bear case is heavy. The failure of WAINUA in ATTR-CM places immense pressure on wholly owned commercial assets to perform, even though nominally significant results in the monotherapy subgroup leave a small window open. Tringolza revenue could dip because of pricing changes before the sHTG launch, and Dawnzera faces a crowded HAE market. Selling, general, and administrative costs will rise as Ionis funds several launches at once.
A new tariff risk adds another open question. Ionis disclosed that a U.S. proclamation in April 2026 imposed tariffs of up to 100 percent on imported patented drugs and active pharmaceutical ingredients. The company is evaluating how much this could raise supply costs.
From royalties to owned launches
Ionis develops antisense medicines. These are drugs designed to bind to RNA, which helps control how the body makes certain proteins. For years, Ionis made much of its money from partners, especially SPINRAZA royalties from Biogen and research payments from drug company collaborations.
That model is changing. Ionis now sells its own drugs in the U.S., including Tryngolza for FCS and sHTG and Dawnzera for HAE. Direct sales can keep more value inside Ionis, but they also require sales teams, market access work, patient support, and more corporate spending.
The company still uses partners where it needs reach or shared cost. AstraZeneca helps commercialize WAINUA, Biogen sells SPINRAZA and QALSODY, Sobi handles Tryngolza in many countries outside the U.S., and Otsuka has Dawnzera rights in Europe and Asia-Pacific.
This mix can work if owned products grow faster than expenses. It can break if launches are slow, insurers limit access, partner milestones do not arrive on time, or tariffs lift manufacturing and supply costs.
The drugs that matter most
Tryngolza, olezarsen
The June 2026 FDA approval in severe hypertriglyceridemia opens a much larger market and is central to the growth case.
Dawnzera, donidalorsen
Dawnzera is Ionis's U.S. launch for preventing hereditary angioedema attacks. Management guided 2026 sales to between $110 million and $120 million.
SPINRAZA
SPINRAZA treats spinal muscular atrophy and is sold by Biogen. It remains the largest royalty source.
WAINUA, eplontersen
WAINUA treats hereditary ATTR polyneuropathy and is partnered with AstraZeneca. A major Phase 3 trial for ATTR cardiomyopathy failed in July 2026.
Zilganersen
Zilganersen is under FDA review for Alexander disease. Its PDUFA date is September 22, 2026.
Obudanersen, ION582
Obudanersen is in Phase 3 development for Angelman syndrome. Enrollment completed in mid-2026.
QALSODY
QALSODY treats a genetic cause of ALS and is sold by Biogen in the U.S. and Europe. Ionis earns royalties rather than running the launch itself.
Q1 2026 revenue mix
Ionis reports one operating segment, but Q1 2026 revenue is disclosed by stream. Collaboration revenue can shift sharply when milestones land.
What could go wrong
Tryngolza launch stalls
High impact · Medium oddsThe sHTG approval greatly expands Tryngolza's addressable market, but approval does not equal sales. Doctors need to adopt it, payers need to cover it, and patients need to start and stay on therapy.
Launch costs outrun revenue
High impact · Medium oddsIonis is building a larger commercial company while still funding research. If new product sales do not ramp quickly, the path to cash flow breakeven by 2028 could slip.
Dawnzera gets squeezed in HAE
Medium impact · Medium oddsHereditary angioedema already has established treatments. Dawnzera's dosing profile may help, but patients and doctors may stay with known options. A slower launch would weaken the claim that Ionis can become a strong direct seller.
Further clinical pipeline setbacks
High impact · Medium oddsThe WAINUA trial failure in July 2026 demonstrated the severe risk of relying on late-stage clinical readouts. Further failures would hurt sentiment and future revenue expectations.
Tariffs lift supply costs
Medium impact · Medium oddsIonis disclosed that tariffs of up to 100 percent on imported patented pharmaceutical products and active pharmaceutical ingredients were announced in April 2026. The company has not yet quantified the impact.
In one breath
What does Ionis Pharmaceuticals do?
Ionis makes RNA-targeted medicines, mainly antisense drugs. These drugs are designed to change how the body makes disease-related proteins.
Why does Tryngolza matter so much for Ionis?
Tryngolza is Ionis's first wholly owned medicine with a multibillion-dollar peak sales target from management. Its sHTG approval in June 2026 turns Ionis from a mainly royalty and R&D company into a bigger commercial execution story.
Is Ionis profitable?
Ionis is still in an investment phase. In Q1 2026, it reported a net loss of $92.5 million while spending heavily on product launches and research.
What should investors watch next?
The most important near-term items are Tryngolza sHTG launch sales, Dawnzera uptake, the September 22, 2026 FDA decision for zilganersen, and cardiovascular data from pelacarsen.
